Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
2 Acute myeloid leukemia 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
3 Acute myeloid leukemia 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
4 Adipocytokine signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
5 Adrenergic signaling in cardiomyocytes 💬
2件: ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
6 Adrenergic signaling in cardiomyocytes 💬
2件: ADRB1, ADRB2 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
8 Alcoholism 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
9 Aldosterone-regulated sodium reabsorption 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
10 Alzheimer disease 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
11 Alzheimer disease 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
12 Alzheimer disease 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
13 Amoebiasis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
14 AMPK signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
15 AMPK signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
16 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
17 Apelin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
18 Apelin signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
19 Apoptosis 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
20 Apoptosis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
21 Autophagy - animal 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
22 Autophagy - animal 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
23 Autophagy - animal 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
24 Autophagy - other 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
25 Axon guidance 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
26 B cell receptor signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
27 B cell receptor signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
28 Bacterial invasion of epithelial cells 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
29 Bladder cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
30 Breast cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
31 Breast cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
32 Breast cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
33 C-type lectin receptor signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
34 Calcium signaling pathway 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
35 Calcium signaling pathway 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
36 cAMP signaling pathway 💬
2件: ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
37 cAMP signaling pathway 💬
2件: ADRB1, ADRB2 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
38 cAMP signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
39 cAMP signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
40 Carbohydrate digestion and absorption 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
41 Cellular senescence 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
42 Cellular senescence 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
43 Cellular senescence 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
44 Central carbon metabolism in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
45 Central carbon metabolism in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
46 Central carbon metabolism in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
47 cGMP-PKG signaling pathway 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
48 cGMP-PKG signaling pathway 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
49 cGMP-PKG signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
50 cGMP-PKG signaling pathway 💬
1件: PDE5 💬 Sildenafil citrate 💬 Sildenafil 14件:  6 , 46, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 💬
51 cGMP-PKG signaling pathway 💬
1件: PDE5 💬 Sildenafil 💬 Sildenafil 14件:  6 , 46, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 💬
52 Chagas disease 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
53 Chemical carcinogenesis - reactive oxygen species 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
54 Chemical carcinogenesis - reactive oxygen species 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
55 Chemical carcinogenesis - receptor activation 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
56 Chemical carcinogenesis - receptor activation 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
57 Chemical carcinogenesis - receptor activation 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
58 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
59 Chemical carcinogenesis - receptor activation 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
60 Chemokine signaling pathway 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
61 Chemokine signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
62 Choline metabolism in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
63 Choline metabolism in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
64 Choline metabolism in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
65 Cholinergic synapse 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
66 Cholinergic synapse 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
67 Chronic myeloid leukemia 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
68 Chronic myeloid leukemia 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
69 Colorectal cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
70 Colorectal cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
71 Colorectal cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
72 Coronavirus disease - COVID-19 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
73 Cushing syndrome 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
74 Diabetic cardiomyopathy 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
75 Diabetic cardiomyopathy 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
76 Dilated cardiomyopathy 💬
1件: ADRB1 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
77 Dilated cardiomyopathy 💬
1件: ADRB1 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
78 Efferocytosis 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
79 Endometrial cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
80 Endometrial cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
81 Epstein-Barr virus infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
82 ErbB signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
83 ErbB signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
84 ErbB signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
85 Estrogen signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
86 Estrogen signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
87 Fc epsilon RI signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
88 Fc epsilon RI signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
89 Fc gamma R-mediated phagocytosis 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
90 Fc gamma R-mediated phagocytosis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
91 Fluid shear stress and atherosclerosis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
92 Focal adhesion 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
93 Focal adhesion 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
94 FoxO signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
95 FoxO signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
96 Gap junction 💬
1件: ADRB1 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
97 Gap junction 💬
1件: ADRB1 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
98 Gap junction 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
99 Gastric cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
100 Gastric cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
101 Gastric cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
102 Glioma 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
103 Glioma 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
104 Glioma 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
105 GnRH secretion 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
106 GnRH secretion 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
107 GnRH signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
108 Growth hormone synthesis, secretion and action 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
109 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
110 Growth hormone synthesis, secretion and action 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
111 Hepatitis B 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
112 Hepatitis B 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
113 Hepatitis C 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
114 Hepatitis C 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
115 Hepatocellular carcinoma 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
116 Hepatocellular carcinoma 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
117 Hepatocellular carcinoma 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
118 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
119 Herpes simplex virus 1 infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
120 HIF-1 signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
121 HIF-1 signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
122 HIF-1 signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
123 Hormone signaling 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
124 Hormone signaling 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
125 Hormone signaling 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
126 Human cytomegalovirus infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
127 Human cytomegalovirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
128 Human cytomegalovirus infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
129 Human immunodeficiency virus 1 infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
130 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
131 Human immunodeficiency virus 1 infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
132 Human papillomavirus infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
133 Human papillomavirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
134 Human papillomavirus infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
135 Human T-cell leukemia virus 1 infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
136 Human T-cell leukemia virus 1 infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
137 Huntington disease 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
138 Inflammatory mediator regulation of TRP channels 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
139 Influenza A 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
140 Influenza A 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
141 Inositol phosphate metabolism 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
142 Insulin resistance 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
143 Insulin resistance 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
144 Insulin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
145 Insulin signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
146 Insulin signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
147 JAK-STAT signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
148 JAK-STAT signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
149 Kaposi sarcoma-associated herpesvirus infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
150 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
151 Kaposi sarcoma-associated herpesvirus infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
152 Leukocyte transendothelial migration 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
153 Lipid and atherosclerosis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
154 Long-term depression 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
155 Long-term potentiation 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
156 Longevity regulating pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
157 Longevity regulating pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
158 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
159 Longevity regulating pathway - multiple species 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
160 MAPK signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
161 Measles 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
162 Melanogenesis 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
163 Melanoma 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
164 Melanoma 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
165 MicroRNAs in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
166 MicroRNAs in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
167 MicroRNAs in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
168 mTOR signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
169 mTOR signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
170 mTOR signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
171 Natural killer cell mediated cytotoxicity 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
172 Natural killer cell mediated cytotoxicity 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
173 Neuroactive ligand signaling 💬
2件: ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
174 Neuroactive ligand signaling 💬
2件: ADRB1, ADRB2 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
175 Neuroactive ligand-receptor interaction 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
176 Neuroactive ligand-receptor interaction 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
177 Neurotrophin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
178 Neurotrophin signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
179 Neutrophil extracellular trap formation 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
180 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
181 Neutrophil extracellular trap formation 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
182 Non-alcoholic fatty liver disease 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
183 Non-small cell lung cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
184 Non-small cell lung cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
185 Oocyte meiosis 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
186 Osteoclast differentiation 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
187 Osteoclast differentiation 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
188 Oxytocin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
189 Pancreatic cancer 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
190 Pancreatic cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
191 Pancreatic cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
192 Parathyroid hormone synthesis, secretion and action 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
193 Pathways in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
194 Pathways in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
195 Pathways in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
196 Pathways of neurodegeneration - multiple diseases 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
197 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
198 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
199 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
200 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
201 Phosphatidylinositol signaling system 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
202 Phospholipase D signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
203 Phospholipase D signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
204 Phospholipase D signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
205 PI3K-Akt signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
206 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
207 PI3K-Akt signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
208 Platelet activation 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
209 Prion disease 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
210 Progesterone-mediated oocyte maturation 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
211 Progesterone-mediated oocyte maturation 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
212 Prolactin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
213 Prolactin signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
214 Prostate cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
215 Prostate cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
216 Prostate cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
217 Proteoglycans in cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
218 Proteoglycans in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
219 Proteoglycans in cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
220 Purine metabolism 💬
1件: PDE5 💬 Sildenafil citrate 💬 Sildenafil 14件:  6 , 46, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 💬
221 Purine metabolism 💬
1件: PDE5 💬 Sildenafil 💬 Sildenafil 14件:  6 , 46, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 💬
222 Rap1 signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
223 Rap1 signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
224 Ras signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
225 Ras signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
226 Regulation of actin cytoskeleton 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
227 Regulation of actin cytoskeleton 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
228 Regulation of lipolysis in adipocytes 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
229 Regulation of lipolysis in adipocytes 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
230 Regulation of lipolysis in adipocytes 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
231 Relaxin signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
232 Relaxin signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
233 Renal cell carcinoma 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
234 Renal cell carcinoma 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
235 Renin secretion 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
236 Renin secretion 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
237 Salivary secretion 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
238 Salivary secretion 💬
3件: ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
239 Salmonella infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
240 Salmonella infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
241 Serotonergic synapse 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
242 Shigellosis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
243 Shigellosis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
244 Signaling pathways regulating pluripotency of stem cells 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
245 Signaling pathways regulating pluripotency of stem cells 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
246 Small cell lung cancer 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
247 Sphingolipid signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
248 Sphingolipid signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
249 Spinocerebellar ataxia 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
250 Spinocerebellar ataxia 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
251 T cell receptor signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
252 T cell receptor signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
253 Th17 cell differentiation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
254 Thermogenesis 💬
1件: ADRB3 💬 Propranolol hydrochloride 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
255 Thermogenesis 💬
1件: ADRB3 💬 Propranolol 💬 Propranolol 7件:  6 , 158, 215, 216, 227, 278, 296 💬
256 Thermogenesis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
257 Thyroid cancer 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
258 Thyroid hormone signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
259 Thyroid hormone signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
260 Thyroid hormone signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
261 TNF signaling pathway 💬
1件: MAP2K1 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
262 TNF signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
263 Toll-like receptor signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
264 Toll-like receptor signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
265 Type II diabetes mellitus 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
266 Type II diabetes mellitus 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
267 Vascular smooth muscle contraction 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
268 VEGF signaling pathway 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
269 VEGF signaling pathway 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
270 Viral carcinogenesis 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬
271 Yersinia infection 💬
2件: MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib 4件: 34, 278, 279, 280 💬
272 Yersinia infection 💬
1件: PIK3CA_B_D 💬 Alpelisib 💬 Alpelisib 4件: 138, 278, 279, 280 💬